Stay tuned to this page for the latest in AACP's advocacy efforts and important legislative news impacting pharmacy and pharmacy educators. This page will update bi-weekly in tandem with the AACP E-lert, sent to all AACP members via e-mail.
The Latest in AACP Advocacy
(Published in the Mar. 19 E-lert)
Complete the Pharmacy-based Vaccine Services Pulse Survey
AACP is reaching out on behalf of the pharmacy‑based vaccine access work group, composed of your national pharmacy organizations, to invite you to participate in an important survey. The purpose of this survey is to gather insights into vaccination practices since June 2025. Your experiences are essential in helping us understand current challenges and trends in your practice setting. The deadline to complete this survey is March 31st by 11:59 pm ET.
Court Blocks HHS Changes to Childhood Vaccine Schedule
On March 16, 2026, a federal court issued a preliminary injunction blocking most of the vaccine recommendations and changes issued and approved by HHS via CDC and ACIP since May 2025, while the lawsuit moves forward. This means, changes to the CDC childhood vaccine schedules are on hold, new ACIP appointments are under further review, and any decisions voted on by new members are suspended. AACP continues to support the American Academy of Pediatrics and fellow national pharmacy organizations to monitor and respond to the rapidly evolving vaccine policy landscape.
UMR Releases 2026 Annual Economic Report
Commissioned by United for Medical Research (UMR), “NIH’s Role in Sustaining the U.S. Economy: Creating Jobs and Strengthening Local Economies” is an annual analysis of jobs and economic activity supported by National Institutes of Health (NIH) research funding distributed to all 50 U.S. states and the District of Columbia. According to their latest report, published this month, NIH research funding supported 390,863 jobs and produced $94.15 billion in new economic activity nationwide in 2025. For every $1 invested in NIH research, there was $2.57 generated in economic activity – a 250% return. Access the full report here and the toolkit to educate your community.
Join the NIH Webinar on Fiscal Years 2027-2031 Strategic Plan
On March 16, 2026, the NIH released a request for information notice highlighting ”the purpose of the NIH-Wide Strategic Plan is to communicate how NIH will advance its mission to support research in pursuit of fundamental knowledge about the nature and behavior of living systems, and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The current NIH-Wide Strategic Plan, covering FY21-FY25, was submitted to Congress in July 2021. As part of implementing the 21st Century Cures Act (P.L. 114-255), NIH will update its Strategic Plan, no less than once every six years. The agency is currently developing the NIH-Wide Strategic Plan for FY27-FY31 and anticipates releasing it early FY27.” Join the NIH webinar on April 8, from 2:30 to 3:30 p.m. ET, as they introduce the process for developing the next NIH-wide strategic plan. Review the RFI and Comment Opportunities section for additional information.
AACP Joins Friends of NIAID in FY27 Appropriations Letter
On March 9, 2026, AACP joined the American Society for Microbiology and other national and state organizations in requesting at least $7.15 billion for the National Institute of Allergy and Infectious Diseases (NIAID) and at least $51.3 billion for the National Institutes of Health overall for fiscal year (FY) 2027 representing an 8.7% increase over FY26 levels. Thanks to long-term and sustained support from Congress for NIAID over the years, the U.S. has achieved major victories over deadly, disabling, and costly diseases. Read the letter here.
ORI Publishes Research Misconduct Final Rule
On March 5, The Office of Research Integrity (ORI) released new guidance documents to support institutional compliance with the updated Public Health Service Policies on Research Misconduct (42 CFR Part 93), which took effect January 1, 2026. The newly released documents address three key areas of research misconduct: confidentiality, interviews, and subsequent use exceptions. Note: some of the newly released guidance cross-reference other guidance documents that have not yet been released. Users can expect these referenced guidance documents to be released in the near future. Visit the ORI Guidance Documents website for more information.
FDA Announces Adverse Event Monitoring System (AEMS) Launch
In September 2025, the FDA introduced the idea of consolidating the agency’s product-specific adverse event data systems into a single unified system to be known as the Adverse Event Monitoring System, or AEMS The agency’s product-specific systems include the FDA Adverse Event Reporting System, or FAERS, for drugs, biological products, cosmetics and color additives; the Vaccine Adverse Event Reporting System, or VAERS; the Manufacturer and User Facility Device Experience, or MAUDE, database; the Adverse Event Reporting System, or AERS, for animal drugs and foods; and the Human Food Complaint System, or HFCS. The agency announced that it was moving ahead with the plan, renaming the FAERS system “AEMS.” The AEMS webpage now states that the system was “formerly” FAERS. Read the FDA’s press release for more information.
National Health Service Corps (NHSC) Loan Repayment Programs Applications Open
The NHSC is now accepting applications for loan repayment programs including the NHSC Substance Use Disorder Workforce Loan Repayment Program and the NHSC Rural Community Loan Repayment Program. Review the eligibility criteria and visit the Health Resources and Services Administration's comparison chart to find the right program for you. If you are a pharmacist working in an NHSC-approved site, you could receive up to $100,000 to pay off your student loans. The application deadline is Tuesday, March 31 at 7:30 p.m. ET.
Request for Information and Comment Opportunities
*AACP will continue to inform members of new and ongoing comment opportunities as information becomes available. Mention of these opportunities does not indicate AACP’s intention to submit comments.
- [NEW] The Food and Drug Administration issued a RFI seeking public comment on potential new standards for in-home opioid disposal products. This effort is part of the agency’s broader work to combat the opioid crisis. The Agency is currently considering exercising its authority to require, through a Risk Evaluation and Mitigation Strategy (REMS), that a drug be dispensed to certain patients with safe disposal packaging or a safe disposal system. The purpose of this notice is to seek public comment on what specifications would be necessary to show that in-home disposal systems may mitigate the serious risks of abuse or overdose involving these medications. The comment deadline ends April 6, 2026.
- The Health Resources and Services Administration has released a request for information on the 340B Rebate Model Pilot Program. According to the Federal Register notice, the RFI “seeks comments on whether HRSA should implement a rebate model under the 340B Program and how best to operationalize any such rebate framework for stakeholders. The information collected through this RFI will assist HRSA in evaluating the operational, financial, and access to drugs for patients of a rebate model on covered entities, manufacturers, and other stakeholders across the drug supply chain.” The comment deadline has been extended to April 20, 2026.
- [NEW] The National Institutes of Health invites comments and suggestions on a Framework for the NIH-Wide Strategic Plan for Fiscal Years 2027-2031. The framework articulates NIH’s Priorities in three key areas: (1) biomedical and behavioral science research; (2) scientific research capacity; and (3) scientific research operations. Read more about the goals for each priority here and the submit comments by May 16, 2026, via the submission website.
- The Food and Drug Administration announced the following public workshop entitled “Fiscal Year 2026 Generic Drug Science and Research Initiatives Workshop.” The purpose of the public workshop is to provide an overview of the status of science and research initiatives for generic drugs and an opportunity for public input on these initiatives. The public workshop will be held on June 8 and 9, 2026. Either electronic or written comments on this public workshop must be submitted by July 10, 2026.